K. Cohen

发表

A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

L. Stamatatos, A. McGuire, M. Neradilek, 2021, medRxiv.

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial

Shuying S Li, M. McElrath, J. McElrath, 2018, PloS one.

Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies

Aaron M. Seese, Abigail Wall, A. McGuire, 2020, Journal of Immunological Methods.

Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

L. Stamatatos, D. Montefiori, M. Gray, 2021, bioRxiv.

PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection

S. Hoffman, J. Kublin, T. Richie, 2021, PLoS pathogens.

Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial

Lindsay N. Carpp, Allan C. deCamp, S. Hammer, 2019, Journal of Virology.

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans

Lindsay N. Carpp, L. Zhao, N. Frahm, 2020, PloS one.

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.

H. Schuitemaker, N. Frahm, M. McElrath, 2016, JAMA.

Impairment of CD1d-restricted natural killer T cells in chronic HIV type 1 clade C infection.

M. Altfeld, B. Walker, T. Ndung’u, 2010, AIDS research and human retroviruses.

A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

L. Stamatatos, A. McGuire, M. Neradilek, 2021, medRxiv : the preprint server for health sciences.

Isolation and Characterization of Cross-Neutralizing COVID-19+ Subjects

J. Mascola, L. Stamatatos, A. McGuire, 2021 .

HLA-I associated adaptation dampens the CD8 T-cell response in HIV Ad5-vectored vaccine recipients.

A. Fiore-Gartland, P. Goepfert, A. Bansal, 2019, The Journal of infectious diseases.

Persistent serum protein signatures define an inflammatory subset of long COVID

T. Torgerson, M. McElrath, E. Newell, 2022, bioRxiv.

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

A. Mehta, M. McElrath, J. Wrammert, 2021, medRxiv.

RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial

M. McElrath, J. Harezlak, C. Valim, 2017, Front. Immunol..

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens

Lindsay N. Carpp, S. Buchbinder, M. McElrath, 2022, EBioMedicine.

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

H. Schuitemaker, P. van Damme, M. McElrath, 2021, The New England journal of medicine.

Matrix Metalloprotease Inhibitors Restore Impaired NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Human Immunodeficiency Virus Type 1 Infection

B. Walker, G. Alter, S. Rihn, 2009, Journal of Virology.

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

A. Mehta, M. McElrath, J. Wrammert, 2021, Cell Reports Medicine.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

J. Kublin, D. Montefiori, N. Frahm, 2018, The lancet. HIV.

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Mathieu Le Gars, H. Schuitemaker, P. van Damme, 2020, medRxiv.

HIV-1 Single-Stranded RNA Induces CXCL13 Secretion in Human Monocytes via TLR7 Activation and Plasmacytoid Dendritic Cell–Derived Type I IFN

L. Stamatatos, M. McElrath, G. Alter, 2015, The Journal of Immunology.

Achieving intracellular cytokine staining assay concordance on two continents to assess HIV vaccine‐induced T‐cell responses

M. McElrath, Yunda Huang, V. Voillet, 2022, Journal of leukocyte biology.

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

M. McElrath, S. D. De Rosa, M. Pau, 2022, PloS one.

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis

J. Mascola, D. Montefiori, R. Coler, 2022, Research square.

EBV-Specific Donor Cells Transduced to Express a High-Affinity WT1 TCR Can Prevent Recurrence in Post-HCT Patients with High-Risk AML

M. Bar, P. Greenberg, D. Banker, 2016 .

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

Thomas M. Schmitt, M. Bar, R. Gottardo, 2019, Nature Medicine.

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

Allan C. deCamp, J. Kublin, D. Montefiori, 2020, PLoS medicine.

Origin and differentiation of human memory CD8 T cells after vaccination

G. Alexe, W. Greenleaf, M. McElrath, 2017, Nature.

Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence

Lucas T. Graybuck, Olivia Fong, T. Torgerson, 2021, bioRxiv.

Title: Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence Authors:

Lucas T. Graybuck, T. Torgerson, M. McElrath, 2021 .

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

M. McElrath, O. Anzala, D. Heerwegh, 2022, PLoS medicine.

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

M. McElrath, O. Anzala, D. Heerwegh, 2021, PLoS medicine.

Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.

Lindsay N. Carpp, J. Kublin, M. McElrath, 2022, The Journal of infectious diseases.

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

J. Kublin, D. Montefiori, H. Schuitemaker, 2020, The lancet. HIV.

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

A. Mehta, M. McElrath, J. Wrammert, 2021, Cell Reports Medicine.

Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate

M. McElrath, P. Goepfert, C. Gerard, 2022, Clinical & translational immunology.

Immune Correlates of Cross-Reactive Neutralizing Antibodies in HIV-1 Infection

K. Cohen, Kristen W. Cohen, 2014 .

B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques

K. Lathia, L. Stamatatos, D. Sather, 2018, PLoS pathogens.

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

M. Altfeld, G. Leroux-Roels, M. Janssens, 2010, Vaccine.

Ligand-Independent Exhaustion of Killer Immunoglobulin-Like Receptor-Positive CD8+ T Cells in Human Immunodeficiency Virus Type 1 Infection

F. Pereyra, M. Altfeld, B. Walker, 2008, Journal of Virology.

Ligand-Independent Exhaustion of Killer Immunoglobulin-Like Receptor-Positive CD8 (cid:1) T Cells in Human Immunodeﬁciency Virus Type 1 Infection (cid:1)

F. Pereyra, M. Altfeld, B. Walker, 2008 .

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

L. Stamatatos, A. McGuire, M. Neradilek, 2021, Science.

Vaccination induces HIV broadly neutralizing antibody precursors in humans

Allan C. deCamp, Jordan R. Willis, D. Montefiori, 2022, Science.

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

M. Proschan, T. Chun, J. Justement, 2017, Science Translational Medicine.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

S. Hammer, R. Gottardo, S. Buchbinder, 2017, The Journal of infectious diseases.

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies

L. Stamatatos, A. West, A. McGuire, 2013, The Journal of experimental medicine.

Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs

L. Stamatatos, D. Burton, A. McGuire, 2013, PLoS pathogens.

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

L. Stamatatos, A. McGuire, M. McElrath, 2020, Immunity.

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

B. Korber, B. Haynes, D. Montefiori, 2023, The Journal of clinical investigation.

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects

J. Mascola, L. Stamatatos, A. McGuire, 2021, Cell Reports.

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects

J. Mascola, L. Stamatatos, A. McGuire, 2021, bioRxiv.

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

L. Stamatatos, A. McGuire, M. McElrath, 2020, bioRxiv.

Correction: Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs

L. Stamatatos, D. Burton, A. McGuire, 2013, PLoS Pathogens.

Shared HIV envelope-specific B cell clonotypes induced by a pox-protein vaccine regimen

M. McElrath, O. Hyrien, Z. Moodie, 2021 .

AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.

D. Montefiori, S. Buchbinder, M. McElrath, 2021, Vaccine.

Current views on the potential for development of a HIV vaccine

N. Frahm, K. Cohen, Kristen W. Cohen, 2017, Expert opinion on biological therapy.

Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial

B. Haynes, W. Fischer, N. Frahm, 2021, The Journal of clinical investigation.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA

R. Gottardo, N. Frahm, Greg Finak, 2017, Clinical and Vaccine Immunology.

Early Preservation of CXCR5+ PD-1+ Helper T Cells and B Cell Activation Predict the Breadth of Neutralizing Antibody Responses in Chronic HIV-1 Infection

M. Altfeld, L. Stamatatos, G. Alter, 2014, Journal of Virology.

Early Preservation of CXCR 5 PD-1 Helper T Cells and B Cell Activation Predict the Breadth of Neutralizing Antibody Responses in Chronic HIV-1 Infection

M. Altfeld, L. Stamatatos, G. Alter, 2014 .

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

J. Kublin, D. Montefiori, H. Schuitemaker, 2022, The Journal of infectious diseases.

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

J. Kublin, D. Montefiori, N. Frahm, 2020, PLoS medicine.

A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses

Allan C. deCamp, R. Koup, Greg Finak, 2023, Science Translational Medicine.

Persistent serum protein signatures define an inflammatory subcategory of long COVID

T. Torgerson, E. Coffey, S. Vasaikar, 2023, Nature communications.

Th2-Biased Transcriptional Profile Predicts HIV Envelope-Specific Polyfunctional CD4+ T Cells That Correlated with Reduced Risk of Infection in RV144 Trial

R. Gottardo, M. McElrath, S. D. De Rosa, 2022, The Journal of Immunology.